Filing Overview
The submitted Form 8-K is for Tivic Health Systems, Inc., not Valion Bio, Inc. It reports events dated July 10, 2023, with the offering closing July 11, 2023. The company is listed on Nasdaq under ticker TIVC.
Material Financing and Key Metrics
- The company agreed to sell up to 32.5 million common shares at $0.055 per share.
- Gross offering proceeds were approximately $1.8 million.
- Net proceeds were approximately $1.6 million after placement-agent fees, expenses, and estimated offering costs.
- Management intends to use the proceeds for working capital and general corporate purposes.
- Maxim Group LLC received an 8.0% cash fee, or approximately $143,000, plus $90,000 for expense reimbursement.
- The company issued Maxim warrants to purchase up to 1.3 million shares at an exercise price of $0.066 per share. The warrants expire five years from the commencement of sales, are exercisable beginning six months after closing, and represent potential additional dilution.
Material Changes and Other Terms
- The financing materially increased the number of common shares outstanding; the filing text does not provide the pre-offering share count or resulting ownership percentages.
- The offering was conducted under the company’s effective Form S-3 shelf registration statement.
- The placement-agent warrants and underlying shares were issued in an unregistered transaction under Section 4(a)(2) and/or Regulation D.
- The company agreed to a 30-day restriction on certain additional securities issuances, subject to exceptions.
- Officers and directors entered into 30-day lock-up agreements covering securities they hold, subject to exceptions.
Financial Results, Liquidity, Outlook, and Risks
This Form 8-K does not report revenue, net income, operating cash flow, margins, total debt, cash balances, or other periodic financial results. The filing text does not provide a clear liquidity runway or quantitative forecast.
The primary financing risk is potential shareholder dilution from the 32.5 million shares sold and the 1.3 million placement-agent warrants. The company also remains subject to customary closing conditions, representations, warranties, indemnification obligations, and ongoing covenants under the transaction documents. No specific business outlook or updated guidance is provided.
Investor Verification Items
- Confirm the intended company identity, because the request identifies Valion Bio, Inc., while the filing identifies Tivic Health Systems, Inc.
- Verify the final number of shares issued and the resulting shares outstanding after the July 11, 2023 closing.
- Review the Purchase Agreement, Placement Agency Agreement, and warrant terms for additional covenants, termination rights, and indemnification provisions.
- Assess the company’s cash balance, burn rate, debt, and expected runway using its latest periodic filing; these figures are not included in this 8-K.
- Evaluate the effect of the offering and potential warrant exercise on dilution and future financing needs.